Is this a revolution in Alzheimer's?

This week on The Pharma Letter Podcast, we’re joined by Howard Fillit, co-founder and chief science officer at the Alzheimer’s Drug Discovery Foundation (ADDF).As the FDA approval of anti-amyloid drugs like lecanemab and donanemab marks a new era in the treatment of Alzheimer’s, questions remain around cost, access, and real-world impact. A geriatrician and neuroscientist, Dr Fillit has argued for a broader approach to Alzheimer’s—one that targets not just amyloid, but the full biology of aging.Dr Fillit and the ADDF are working to expand the therapeutic toolbox, backing research into novel mechanisms, smarter diagnostics, and more efficient trial designs.With new interest in combination therapies, biomarker-driven care, and risk-reduction strategies, the field is evolving fast. In this episode, we’ll talk about what’s coming next in Alzheimer’s R&D, and how philanthropy, biotech, and science are converging to shape the future of care.